文献速递药物相互作用特殊人群用药

老年患者低剂量甲氨蝶呤与复方磺胺甲噁唑联用与30天死亡风险:队列研究

Co-prescription of low-dose methotrexate and trimethoprim-sulfamethoxazole and the 30-day risk of death among older adults: A cohort study.
PubMed 文献 · Br J Clin Pharmacol · 2024-12-08

该回顾性队列研究在加拿大安大略省纳入1602例联用低剂量甲氨蝶呤与TMP-SMX的老年患者,并按1:1匹配联用头孢菌素者,发现30天死亡风险无显著差异(RR 0.93,95%CI 0.45-1.93),但全因住院和持续感染住院风险更高。

要点

  • 老年患者联用低剂量甲氨蝶呤与TMP-SMX相比头孢菌素,30天死亡风险未见升高(RR 0.93,95%CI 0.45-1.93)。
  • 联用TMP-SMX相比头孢菌素与更高的30天全因住院风险相关(RR 1.49,95%CI 1.13-1.97)。
  • 联用TMP-SMX相比头孢菌素与更高的30天持续感染住院风险相关(RR 2.78,95%CI 1.30-5.95)。

核心结论

  • 在服用低剂量甲氨蝶呤的老年患者中,联用TMP-SMX相比头孢菌素与30天死亡风险升高无关,但与应用头孢菌素相比,与30天全因住院和持续感染住院风险升高相关。

研究设计与样本

  • 加拿大安大略省开展的回顾性、基于人群的新使用者队列研究,时间范围为2002年4月1日至2022年8月1日,使用关联的行政医疗数据。
  • 服用低剂量甲氨蝶呤且新联用TMP-SMX的老年患者1602例,按1:1匹配新联用头孢菌素者,采用倾向性评分匹配平衡基线健康指标,使用改良泊松回归计算风险比。

主要发现

  • 在3204例倾向性评分匹配的服用低剂量甲氨蝶呤的成人队列中,联用TMP-SMX组30天死亡14/1602(0.87%),联用头孢菌素组15/1602(0.94%),风险比RR 0.93(95%CI 0.45-1.93)。
  • 联用TMP-SMX组相比头孢菌素组,全因住院风险RR 1.49(95%CI 1.13-1.97),以持续感染为主要诊断的住院风险RR 2.78(95%CI 1.30-5.95)。

临床怎么用

  • 老年患者服用低剂量甲氨蝶呤时如需联用TMP-SMX,应权衡联用TMP-SMX的获益与观察到的全因住院及持续感染住院风险升高。
  • 联用TMP-SMX期间应关注住院风险,尤其是持续感染相关住院,但30天死亡风险未见显著升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to characterize the risk of death in older adults co-prescribed low-dose methotrexate and TMP-SMX vs. low-dose methotrexate and a cephalosporin. METHODS: We conducted a retrospective, population-based, new-user cohort study in Ontario, Canada (April 1, 2002-August 1, 2022) using linked administrative healthcare data. Older adults taking low-dose methotrexate who were newly co-prescribed TMP-SMX (n = 1602) were matched 1:1 with those who were newly co-prescribed a cephalosporin. The primary outcome was death within 30 days of the antibiotic dispensing date. Secondary outcomes included all-cause hospitalization, a hospital visit with myelosuppression and a hospitalization with persistent infection defined as the main diagnosis. Propensity score matching was used to balance comparison groups on indicators of baseline health. Risk ratios (RR) were obtained using modified Poisson regression. RESULTS: In a propensity-score matched cohort of 3204 adults taking low-dose methotrexate, the 30-day risk of death was similar in adults co-prescribed TMP-SMX vs. a cephalosporin (14/1602 [0.87%] vs. 15/1602 [0.94%]; RR 0.93 [95% CI 0.45-1.93]). The risk of all-cause hospitalization (RR 1.49 [95% CI 1.13-1.97]) and infection (RR 2.78 [95% CI 1.30-5.95]) was higher in adults treated with TMP-SMX than those treated with cephalosporins. CONCLUSIONS: In older adults taking low-dose methotrexate, co-prescription of TMP-SMX vs. a cephalosporin was not associated with a higher 30-day risk of death but was associated with a higher 30-day risk of all-cause hospitalization and hospital admission with persistent infection. If verified, these risks should be balanced against the benefits of co-prescribing TMP-SMX and low-dose methotrexate.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sadeghi H, Ahmadi F, McArthur E, et al. Co-prescription of low-dose methotrexate and trimethoprim-sulfamethoxazole and the 30-day risk of death among older adults: A cohort study. Br J Clin Pharmacol. 2024. PMID: 39647844. doi:10.1111/bcp.16365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。